ACS Local Section
New York
Westchester Chemical Society

THE CRITICAL ATTRIBUTES OF TUNABLE LACTIDE/GLYCOLIDE POLYMERS THAT DRIVE THE PERFORMANCE OF LONG-ACTING INJECTABLES

Speaker: **Tom Tice, Ph.D.**

Senior Director,
Global Strategic and
Technical Marketing,
Evonik Corporation

Date: **Thursday, February 12, 2026**

Time: 7:30 pm

Place: ONLINE ONLY via ZOOM

ZOOM link to be provided before the event

Event is free of charge

Please contact Peter Corfield at pcorfield@fordham.edu to RSVP for the meeting or if you have any questions.

ACS Local Section
New York
Westchester Chemical Society

THE CRITICAL ATTRIBUTES OF TUNABLE LACTIDE/GLYCOLIDE POLYMERS THAT DRIVE THE PERFORMANCE OF LONG-ACTING INJECTABLES

Abstract:
There are a small number of established pharmaceutical excipients that will continue to be cornerstones of drug formulation for the foreseeable future. Lactide/glycolide polymers (PLG polymers) are members of this unique group of proven excipients. PLG polymers have a long safety record with many inherent properties that make them particularly advantageous for complex parenteral drug products such as long-acting injectables, including microparticle, implant and in situ forming dosage forms. PLG polymers are exceptional in that their properties can be precisely tuned to achieve desired formulation performance for systemic or local delivery of all classes of drugs - including small molecules, peptides, proteins and nucleic acids - for durations of weeks and months. Although PLG polymers were invented over 90 years ago and have been used in medical products for over 50 years, their utility is sometimes overlooked and not fully appreciated. The goal of this presentation is to educate formulators - especially the next-generation of formulators - on the extraordinary value of PLG polymers because understanding PLG critical attributes helps formulators specify the PLGs they would like synthesized by their PLG suppliers. In addition to long-acting dosage forms, future PLG-based products like polymeric nanoparticles for immunotherapy will be discussed as well the newly published PLG monographs and PLG nomenclature.

Follow us on our Facebook page at Westchester Chapter of the ACS

ACS Local Section
New York
Westchester Chemical Society

THE CRITICAL ATTRIBUTES OF TUNABLE LACTIDE/GLYCOLIDE POLYMERS THAT DRIVE THE PERFORMANCE OF LONG-ACTING INJECTABLES

Biography:

Thomas R. Tice, PhD, Senior Director, Global Strategic and Technical Marketing, Evonik Corporation, provides scientific support to Evonik's product development, sales, M&A, and intellectual property teams. Dr. Tice is internationally recognized for his research and drug product development in the field of drug delivery. He has lectured on the topic throughout the world. His specialties include complex parenteral dosage forms formulated with bioabsorbable polymers. He has 47 years of experience developing long-acting injectable microparticles and implants made with bioabsorbable lactide/glycolide polymers. He is one of the inventors of the first commercial, bioabsorbable long-acting injectable microparticle product. Dr. Tice holds 49 US patents and has more than 230 publications, presentations and invited lectures to his credit. He has served on United States Pharmacopeia expert committees for 20 years dedicated to improving global health through setting pharmaceutical standards. He is presently serving on the General Chapters Dosage Forms Expert Committee, Excipients Nomenclature and Labeling Joint Subcommittee and LG Polymers Joint Subcommittee. In 2025, Dr. Tice received USP's highest award, the Beal Award, for distinguished volunteer service.

With attendance at this event, attendees agree to ACS Volunteer and Participant Code of Conduct Policy (https://www.acs.org/volunteer/explore/code-of-conduct.html and Youth Protection Policy (https://www.acs.org/content/dam/acsorg/volunteer/documents/acs-youth-protection-policy.pdf), as applicable